Edition:
United Kingdom

People: Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

12.76USD
9:00pm BST
Change (% chg)

$-0.32 (-2.45%)
Prev Close
$13.08
Open
$13.10
Day's High
$13.10
Day's Low
$12.75
Volume
134,343
Avg. Vol
240,707
52-wk High
$19.48
52-wk Low
$9.14

Gala, Renee 

Ms. Renee D. Gala is an Independent Director of Corcept Therapeutics Incorporated. She has been the Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc., a publicly-traded biopharmaceutical company, since July 2014. From 2006 to June 2014, Ms. Galá held various roles in the finance organization before leading the separation of the biopharmaceutical business (now Theravance Biopharma) from the royalty company, Innoviva, Inc. Prior to joining Theravance, Ms. Galá held positions in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company, a publicly-traded drug manufacturing company, from 2001 to 2006. Before that, Ms. Galá worked for seven years in the energy industry, both in the U.S. and internationally, in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Galá received a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.

Basic Compensation

Total Annual Compensation, USD 55,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 212,889
Fiscal Year Total, USD 267,889

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Wilson

758,669

Joseph Belanoff

6,314,620

Gary Robb

2,845,670

Sean Maduck

2,806,070

Andreas Grauer

--

George Baker

267,889
As Of  31 Dec 2018